Date: 2016-04-18
Type of information: Preclinical data
phase: preclinical
Announcement: preclinical data
Company: Halozyme Therapeutics (USA - CA)
Product: PEG-ADA2
Action
mechanism: immune checkpoint inhibitor.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 18, 2016, Halozyme Therapeutics announced preclinical data for the discovery and early development of an immune checkpoint inhibitor targeting adenosine. PEGylated adenosine deaminase 2, or PEG-ADA2, an immune checkpoint inhibitor targets immuno-suppressive adenosine, which may accumulate to high levels in the tumor microenvironment. PEG-ADA2 is currently in early preclinical development with the next milestone expected to be final drug candidate selection by the end of 2016. Halozyme's PEG-ADA2 was engineered to decrease the concentration of adenosine in the tumor microenvironment, and PEGylated to prolong its circulation in the body. Accumulation of adenosine is believed to contribute to a suppressed immune response to certain solid tumors. In preclinical studies, Halozyme's PEG-ADA2 demonstrated tumor growth inhibition in certain colon, lung and pancreatic cancer models. Treatment with PEG-ADA2 resulted in an increase in infiltration of T cells and lowering of tumor adenosine levels. Halozyme scientists have also identified a potential biomarker for tumors that may respond to PEG-ADA2 therapy. The company plans to continue its ongoing study and characterization of PEG-ADA2 with the goal of determining its suitability as a targeted therapy for clinical study.
